CellCentric develops novel small molecule inhibitors to combat cancerp300/CBP bromodomain inhibitors
Our work draws on a foundation in epigenetics and its application to novel drug discovery.
CellCentric’s small molecule drug candidate binds to the conserved bromo-domain of p300/CBP, and significantly reduces the key drivers of castration resistant prostate cancer. These include the androgen receptor (AR), AR-splice variants and c-Myc.
Targeting p300/CBP is also relevant to the treatment of other cancers including haematological, lung and bladder.
Therapeutic targeting of the p300/CBP bromodomain for the treatment of castration resistant prostate cancer (CRPC)
Targeting the bromodomain of p300/CBP for the treatment of castrate resistant prostate cancer
Characterisation of CCS1477: A novel mall molecule inhibitor of p300/CBP for the treatment of CRPC
Novel small molecule inhibitors of p300/CBP down-regulate AR and c-Myc for the treatment of CRPC
A novel small molecule inhibitor of p300/CBP for the treatment of CRPC – preclinical evaluation
CellCentric’s team has deep experience of drug discovery and development, as well as business collaboration
CCS1477; new collaborations announced exploring p300/CBP inhibition for prostate cancer treatment
January 31st 2018
CellCentric and The Institute of Cancer Research, London, have signed a research agreement to further explore the effects of CellCentric’s drug candidate CCS1477 on prostate cancer. In addition, Karen Knudsen, Johann de Bono and Myles Brown have been granted a Prostate Cancer Foundation challenge award of $1m to investigate the molecular and biological effects of CCS1477 in the context of clinical impact.
CellCentric’s p300/CBP bromodomain inhibitor is clearly differentiated from BET inhibitors
December 4th 2017
CellCentric today presents its latest pre-clinical efficacy data on drug Candidate CCS1477, at the AACR’s Annual Prostate Cancer meeting, Orlando. This novel inhibitor which targets the bromodomain of p300/CBP, is advancing to the clinic early 2018. Latest results continue to support CCS1477’s anti-cancer efficacy, as well as its clear differentiation versus other epigenetic-related inhibitors targeting bromodomains (BET inhibitors), such as JQ-1, iBET-151 and OTX-015.
CellCentric presents at the Prostate Cancer Foundation annual retreat, Washington DC
October 5th 2017
CellCentric presents new data on drug Candidate CCS1477 and its relevance to the aggressive, castrate-resistant form of prostate cancer, at the 24th Annual Prostate Cancer Foundation Scientific Retreat. The PCF meeting is the foremost scientific conference on the biology and treatment of prostate cancer. This is a closed, invitation only event which brings together the best researchers, physicians and medical oncologists from academia, non-profit organisations and industry.
CCS1477 aimed at prostate cancers resistant to 2nd gen anti-hormonals (enza, abi, apa). pic.twitter.com/rZf5XugCfw
PCF Challenge Award underway investigating CCS1477 and p300/CBP bromodomain inhibition for prostate cancer. pic.twitter.com/4A0Z5pU0tQ